Register your practice, schedule a sales rep visit, or order support materials with FIRMAGON Connect.

Sign Up Now

APPROVED FOR ALL STAGES OF APC1,2

Roberto - a patient with locally advanced prostate cancer

ROBERTO, 65

CONTINUOUS ADT*

(FIRMAGON has been studied for up to 12 months.1)

ROBERTO, 65

CONTINUOUS ADT*

(FIRMAGON has been studied for up to 12 months.1)

DIAGNOSIS AND CURRENT VISIT

  • No family history of prostate cancer
  • PSA was 24 ng/mL at initial diagnosis
  • Gleason score: 8 (4+4)
  • Biopsy: 7 of 12 cores positive
  • CT scan with contrast showed positive pelvic lymph nodes
  • Negative bone scan
  • Stage T4, N1, MO

PERSONAL AND FAMILY HISTORY

  • Retired building foreman
  • 2 grown children
  • 5 grandchildren

Hypothetical patient based on patient types studied in clinical trials. The pivotal CS21 study included men aged ≥18 years with histologically confirmed adenocarcinoma of the prostate (all stages), for whom endocrine treatment was indicated (except for neoadjuvant therapy).1

Roberto - a patient with locally advanced prostate cancer

Abbreviations: APC = advanced prostate cancer; PSA = prostate-specific antigen.

Monthly Matters

Help make the most of your patient's treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

I like the regularity of the monthly shot and the chance it gives me to build a relationship with my treatment team.
Actual physician quote

REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.